BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27826159)

  • 1. Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis.
    Kucey M; Bolt J; Albers L; Bell A; Iroh N; Toppings J
    Can J Hosp Pharm; 2016; 69(5):409-414. PubMed ID: 27826159
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
    Fanikos J; Burnett AE; Mahan CE; Dobesh PP
    Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.
    Hawkins NM; Jhund PS; Pozzi A; O'Meara E; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; Virani S; McMurray JJ
    Eur J Heart Fail; 2016 Sep; 18(9):1162-71. PubMed ID: 27594177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Oldgren J
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512140
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
    Pham PN; Brown JD
    BMC Cardiovasc Disord; 2019 Mar; 19(1):64. PubMed ID: 30890131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
    Barra ME; Fanikos J; Connors JM; Sylvester KW; Piazza G; Goldhaber SZ
    Am J Med; 2016 Nov; 129(11):1198-1204. PubMed ID: 27341955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation.
    Manzano-Fernández S; Andreu-Cayuelas JM; Marín F; Orenes-Piñero E; Gallego P; Valdés M; Vicente V; Lip GY; Roldán V
    Rev Esp Cardiol (Engl Ed); 2015 Jun; 68(6):497-504. PubMed ID: 25457087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2018 Jul; 122(1):69-75. PubMed ID: 29681367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure.
    Andreu-Cayuelas JM; Pastor-Pérez FJ; Puche CM; Mateo-Martínez A; García-Alberola A; Flores-Blanco PJ; Valdés M; Lip GY; Roldán V; Manzano-Fernández S
    Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):134-40. PubMed ID: 26607030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia.
    Janion-Sadowska A; Papuga-Szela E; Łukaszuk R; Chrapek M; Undas A
    J Cardiovasc Pharmacol; 2018 Sep; 72(3):153-160. PubMed ID: 29985282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation.
    Andreu Cayuelas JM; Caro Martínez C; Flores Blanco PJ; Elvira Ruiz G; Albendin Iglesias H; Cerezo Manchado JJ; Bailen Lorenzo JL; Januzzi JL; García Alberola A; Manzano-Fernández S
    Eur J Clin Invest; 2018 Jun; 48(6):e12907. PubMed ID: 29423910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which oral anticoagulant for atrial fibrillation.
    Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
    [No Abstract]   [Full Text] [Related]  

  • 20. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
    Wu M; Gabriels J; Khan M; Shaban N; D'Amato S; Liu CF; Markowitz SM; Ip JE; Thomas G; Singh P; Lerman B; Patel A; Cheung JW
    Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.